{
	"slides": {
		"Brintellix_1": {
			"name": "HOMEPAGE",
			"template": "Brintellix_1.html"
		},
		"Brintellix_2": {
			"name": "THREE DOMAINS OF MDD",
			"template": "Brintellix_2.html"
		},
		"Brintellix_3": {
			"name": "TREATMENT GOALS MDD PATIENTS MCNAUGHTON",
			"template": "Brintellix_3.html"
		},
		"Brintellix_4": {
			"name": "STAR D TRIVEDI",
			"template": "Brintellix_4.html"
		},
		"Brintellix_5": {
			"name": "CONRADI COGNITIVE SYMPTOMS PERSIST 94 PERCENT CONRADI",
			"template": "Brintellix_5.html"
		},
		"Brintellix_6": {
			"name": "COGDAD COGNITIVE DYSFUNCTION IN ASIANS CHIN",
			"template": "Brintellix_6.html"
		},
		"Brintellix_7": {
			"name": "TREATMENT SIDE EFFECTS 1 QUARTER OF PATIENTS DISCONTINUE",
			"template": "Brintellix_7.html"
		},
		"Brintellix_8": {
			"name": "ANHEDONIA PREVALENCE IN MDD",
			"template": "Brintellix_8.html"
		},
		"Brintellix_10": {
			"name": "MADRS ASSESSMENT",
			"template": "Brintellix_10.html"
		},
		"Brintellix_11": {
			"name": "PDQ ASSESSMENT",
			"template": "Brintellix_11.html"
		},
		"Brintellix_12": {
			"name": "DSST ASSESSMENT",
			"template": "Brintellix_12.html"
		},
		"Brintellix_13": {
			"name": "SDS ASSESSMENT",
			"template": "Brintellix_13.html"
		},
		"Brintellix_14": {
			"name": "UPSA ASSESSMENT",
			"template": "Brintellix_14.html"
		},
		"Brintellix_15": {
			"name": "SHAPS ASSESSMENT",
			"template": "Brintellix_15.html"
		},
		"Brintellix_16": {
			"name": "EEFRT ASSESSMENT",
			"template": "Brintellix_16.html"
		},
		"Brintellix_17": {
			"name": "MEI ASSESSMENT",
			"template": "Brintellix_17.html"
		},
		"Brintellix_18": {
			"name": "ODQ ASSESSMENT",
			"template": "Brintellix_18.html"
		},
		"Brintellix_19": {
			"name": "GAS D ASSESSMENT",
			"template": "Brintellix_19.html"
		},
		"Brintellix_20": {
			"name": "THASE 11 SHORT TERM STUDIES MADRS SYMPTOMS THASE",
			"template": "Brintellix_20.html"
		},
		"Brintellix_21": {
			"name": "PHYSICAL SYMPTOMS HAM D HAM A CHRISTENSEN",
			"template": "Brintellix_21.html"
		},
		"Brintellix_22": {
			"name": "REMISSION RATE AS 1ST LINE 69 PERCENT 12 WEEKS BOULENGER",
			"template": "Brintellix_22.html"
		},
		"Brintellix_23": {
			"name": "RELAPSE PREVENTION 50 PERCENT FEWER 24 WEEKS BOULENGER",
			"template": "Brintellix_23.html"
		},
		"Brintellix_24": {
			"name": "ALVAREZ SHORT TERM STUDY 6 WEEKS_WTH VENLAFAXINE 225MG ALVAREZ",
			"template": "Brintellix_24.html"
		},
		"Brintellix_25": {
			"name": "LONG TERM STUDY 52 WEEKS SUSTAINED RELIEF FROM SYMPTOMS VIETA",
			"template": "Brintellix_25.html"
		},
		"Brintellix_26": {
			"name": "CIPRIANI METAANALYSIS EFFICACY AND ACCEPTABILITY",
			"template": "Brintellix_26.html"
		},
		"Brintellix_27": {
			"name": "CONNECT PDQ COGNITIVE SYMPTOMS  8 WEEKS MAHABLESHWARKAR",
			"template": "Brintellix_27.html"
		},
		"Brintellix_28": {
			"name": "DSST DIRECT INDIRECT EFFECT COGNITIVE SYMPTOMS MICNTYRE",
			"template": "Brintellix_28.html"
		},
		"Brintellix_29": {
			"name": "BAUNE DSST COMPARISON ANTIDEPRESSANT EFFECT ON COG SYMPTOMS",
			"template": "Brintellix_29.html"
		},
		"Brintellix_30": {
			"name": "LEVEL OF EVIDENCE ON ANTIDEPRESSANT COGNITION EFFECTS MCITNYRE",
			"template": "Brintellix_30.html"
		},
		"Brintellix_31": {
			"name": "SDS FUNCTIONING META ANALYSIS 52 WEEKS  FLOREA",
			"template": "Brintellix_31.html"
		},
		"Brintellix_32": {
			"name": "UPSA CONNECT MAHABLESHWARKAR",
			"template": "Brintellix_32.html"
		},
		"Brintellix_33": {
			"name": "SUMMARY VS DULOXETINE COGNITIVE AND FUNCTIONING ASSESSMENTS",
			"template": "Brintellix_33.html"
		},
		"Brintellix_34": {
			"name": "SHAPS/MADRS ANHEDONIA 8 WEEKS CAO",
			"template": "Brintellix_34.html"
		},
		"Brintellix_35": {
			"name": "EEFRT ANHEDONIA REWARD MOTIVATION SUBRAMANIAPILLAI",
			"template": "Brintellix_35.html"
		},
		"Brintellix_36": {
			"name": "COMPLETE ODQ EMOTIONAL BLUNTING 8 WEEKS FAGIOLINI",
			"template": "Brintellix_36.html"
		},
		"Brintellix_37": {
			"name": "COMPLETE MEI MOTIVATION AND ENERGY 8 WEEKS FAGIOLINI",
			"template": "Brintellix_37.html"
		},
		"Brintellix_38": {
			"name": "GOAL ATTAINMENT BRINTELLIX AS SECOND LINE 12 WEEKS MCCUE",
			"template": "Brintellix_38.html"
		},
		"Brintellix_39": {
			"name": "REVIDA RESPONSE RATE PHQ 9 CGI S 3 MONTHS CHIN",
			"template": "Brintellix_39.html"
		},
		"Brintellix_40": {
			"name": "REVIDA REMISSION RATE PHQ 9 CGI S 3 MONTHS CHIN",
			"template": "Brintellix_40.html"
		},
		"Brintellix_41": {
			"name": "REVIDA DECREASE IN BENZO AND PSYCH MEDICATIONS 3 MONTHS CHIN",
			"template": "Brintellix_41.html"
		},
		"Brintellix_42": {
			"name": "REVIDA PDQ COGNITIVE FUNCTION 3 MONTHS CHIN",
			"template": "Brintellix_42.html"
		},
		"Brintellix_43": {
			"name": "REVIDA WPAI WORK PRODUCTIVITY 3 MONTHS REVIDA CHIN",
			"template": "Brintellix_43.html"
		},
		"Brintellix_44": {
			"name": "ATWORC PDQ DSST WPAI WLQ SCORES 52 WKS CHOKKA",
			"template": "Brintellix_44.html"
		},
		"Brintellix_45": {
			"name": "ATWORC 55 PERCENT FEWER MISSED WORK DAYS 52 WKS CHOKKA",
			"template": "Brintellix_45.html"
		},
		"Brintellix_46": {
			"name": "ATWORCGAD 7 ANXIETY SYMPTOMS REDUCTION 52 WKS CHOKKA",
			"template": "Brintellix_46.html"
		},
		"Brintellix_47": {
			"name": "SOLUTION VS VENLAFAXINE 150MG MADRS 8 WEEKS WANG",
			"template": "Brintellix_47.html"
		},
		"Brintellix_48": {
			"name": "REVIVE PARTIAL RESPONDERS VS AGOMELATINE MADRS MONTGOMERY",
			"template": "Brintellix_48.html"
		},
		"Brintellix_49": {
			"name": "KATONA ELDERLY PATIENTS HAM D 8 WEEKS KATONA",
			"template": "Brintellix_49.html"
		},
		"Brintellix_50": {
			"name": "ALVAREZ HAM A MORE THAN 20 ANXIETY SYMPTOMS 6 WEEKS ALVAREZ",
			"template": "Brintellix_50.html"
		},
		"Brintellix_52": {
			"name": "DOSE EFFECT WORKING POPULATION MADRS SCORE MCINTYRE",
			"template": "Brintellix_52.html"
		},
		"Brintellix_53": {
			"name": "TRAUMA DOSE-DEPENDENT MADRS CHRISTENSEN",
			"template": "Brintellix_53.html"
		},
		"Brintellix_54": {
			"name": "TRAUMA MADRS HAM A SDS SF 36 SYMPTOMS CHRISTENSEN",
			"template": "Brintellix_54.html"
		},
		"Brintellix_55": {
			"name": "TOLERABILITY ICONS SUMMARY",
			"template": "Brintellix_55.html"
		},
		"Brintellix_56": {
			"name": "CANMAT TOLERABILITY TABLE KENNEDY",
			"template": "Brintellix_56.html"
		},
		"Brintellix_58": {
			"name": "NEUROTRANMISSION BRINTELLIX MOA",
			"template": "Brintellix_58.html"
		},
		"Brintellix_59": {
			"name": "DOSING BRINTELLIX",
			"template": "Brintellix_59.html"
		},
		"Brintellix_60": {
			"name": "HIGH DOSE SUMMARY BRINTELLIX",
			"template": "Brintellix_60.html"
		},
		"Brintellix_61": {
			"name": "PHARMACOKINETIC BRINTELLIX",
			"template": "Brintellix_61.html"
		},
		"Brintellix_62": {
			"name": "BRINTELLIX PRESENTATION IMAGES",
			"template": "Brintellix_62.html"
		},
		"Brintellix_63": {
			"name": "BRINTELLIX API",
			"template": "Brintellix_63.html"
		},
		"Brintellix_64": {
			"name": "BIBLIOGRAPHY REFERENCES",
			"template": "Brintellix_64.html"
		},
		"Brintellix_65": {
			"name": "PATIENT CASES",
			"template": "Brintellix_65.html"
		},
		"Brintellix_66": {
			"name": "ROSA WORKING MOTHER PLUS EMOTIONAL BLUNTING",
			"template": "Brintellix_66.html"
		},
		"Brintellix_67": {
			"name": "GANG ENGINEER PLUS ANHEDONIA",
			"template": "Brintellix_67.html"
		},
		"Brintellix_68": {
			"name": "CELINE TEACHER PLUS  TRAUMA",
			"template": "Brintellix_68.html"
		},
		"Brintellix_69": {
			"name": "ANN RETIRED ELDERLY PLUS GOAL ATTAINMENT",
			"template": "Brintellix_69.html"
		},
		"Brintellix_70": {
			"name": "BALDWIN STUDY DESIGN SAFETY AND TOLERABILITY 11 SHORT TERM 5 LONG TERM STUDIES",
			"template": "Brintellix_70.html"
		},
		"Brintellix_71": {
			"name": "MONTGOMERY STUDY DESIGN REVIVE SUBOPTIMAL RESPONSE TO SSRI SNRI",
			"template": "Brintellix_71.html"
		},
		"Brintellix_72": {
			"name": "FLOREA STUDY DESIGN META ANALYSIS SDS 9 SHORT TERM STUDIES",
			"template": "Brintellix_72.html"
		},
		"Brintellix_73": {
			"name": "JACOBSEN STUDY DESIGN LONG TERM STUDY SDS 15MG 20MG",
			"template": "Brintellix_73.html"
		},
		"Brintellix_74": {
			"name": "KATONA STUDY DESIGN ELDERLY EFFICACY TOLERABILITY 5MG",
			"template": "Brintellix_74.html"
		},
		"Brintellix_75": {
			"name": "MAHABLESHWARKAR STUDY DESIGN CONNECT DSST PDQ COGNITIVE FUNCTION",
			"template": "Brintellix_75.html"
		},
		"Brintellix_76": {
			"name": "MCINTYRE STUDY DESIGN FOCUS Z SCORE DSST RAVLT",
			"template": "Brintellix_76.html"
		},
		"Brintellix_77": {
			"name": "ALVAREZ STUDY DESIGN EFFICACY VS VENLAFAXINE PLACEBO 6 WEEKS",
			"template": "Brintellix_77.html"
		},
		"Brintellix_78": {
			"name": "THASE STUDY DESIGN META ANALYSIS 11 TRIALS",
			"template": "Brintellix_78.html"
		},
		"Brintellix_79": {
			"name": "VIETA STUDY DESIGN LONG TERM SAFETY OF BRINTELLIX 52 WEEKS",
			"template": "Brintellix_79.html"
		},
		"Brintellix_80": {
			"name": "WANG STUDY DESIGN SOLUTION ASIAN PATIENTS",
			"template": "Brintellix_80.html"
		},
		"Brintellix_81": {
			"name": "CIPRIANI STUDY DESIGN META ANALYSIS 21 ANTIDEPRESSANTS EFFICACY TOLERABILITY",
			"template": "Brintellix_81.html"
		},
		"Brintellix_82": {
			"name": "CHIN STUDY DESIGN REVIDA MDD IN ASIAN PATIENTS",
			"template": "Brintellix_82.html"
		},
		"Brintellix_83": {
			"name": "CHOKKA STUDY DESIGN ATWORC",
			"template": "Brintellix_83.html"
		},
		"Brintellix_84": {
			"name": "BAUNE STUDY DESIGN META ANALYSIS DSST ANTIDEPRESSANTS",
			"template": "Brintellix_84.html"
		},
		"Brintellix_85": {
			"name": "BOULENGER STUDY DESIGN RELAPSE PREVENTION",
			"template": "Brintellix_85.html"
		},
		"Brintellix_86": {
			"name": "CHRISTENSEN STUDY DESIGN PHYSICAL SYMPTOMS",
			"template": "Brintellix_86.html"
		},
		"Brintellix_87": {
			"name": "JACOBSEN STUDY DESIGN SEXUAL FUNCTIONING CSFQ",
			"template": "Brintellix_87.html"
		},
		"Brintellix_88": {
			"name": "FAGIOLINI STUDY DESIGN EMOTIONAL BLUNTING ODQ",
			"template": "Brintellix_88.html"
		},
		"Brintellix_89": {
			"name": "MCCUE STUDY DESIGN GOAL ACHIEVEMENT",
			"template": "Brintellix_89.html"
		},
		"Brintellix_91": {
			"name": "CHRISTENSEN STUDY DESIGN TRAUMA",
			"template": "Brintellix_91.html"
		},
		"Brintellix_p194": {
			"name": "RECEPTORS BRINTELLIX MOA",
			"template": "Brintellix_p194.html"
		},
		"Brintellix_41Copy2": {
			"name": "BRINTELLIX_DVA_6_SG_V2_Real_world_Data_REVIDA_Anxiety",
			"template": "Brintellix_41Copy2.html",
			"copyFrom": "Brintellix_41"
		},
		"Brintellix_NewAss_2": {
			"name": "EMOTIONAL BLUNTING OF SSRI PATIENTS REPORT",
			"template": "Brintellix_NewAss_2.html"
		},
		"Brintellix_NewAss_3": {
			"name": "RELIEVE SDS 24 WEEKS MATTINGLY",
			"template": "Brintellix_NewAss_3.html"
		},
		"Brintellix_NewAss_4": {
			"name": "MADRS_SDS ANHEDONIA DOSE RESPONSE MCINTYRE",
			"template": "Brintellix_NewAss_4.html"
		},
		"Brintellix_NewAss_6": {
			"name": "HIGH DOSE COMORBID GAD MADRS HAM A 8 WEEKS RECONNECT CHRISTENSEN",
			"template": "Brintellix_NewAss_6.html"
		},
		"Brintellix_NewAss_7": {
			"name": "FLOREA STUDY DESIGN RECONNECT",
			"template": "Brintellix_NewAss_7.html"
		},
		"Brintellix_NewAss_9": {
			"name": "Brintellix_NewAss_9",
			"template": "Brintellix_NewAss_9.html"
		},
		"Brintellix_NewAss_8": {
			"name": "Brintellix_NewAss_8",
			"template": "Brintellix_NewAss_8.html"
		},
		"Brintellix_NewAss_10": {
			"name": "Brintellix_NewAss_10",
			"template": "Brintellix_NewAss_10.html"
		}
	},
	"chapters": {
		"main": {
			"name": "Main chapter",
			"content": [
				"Brintellix_1"
			],
			"chapterExternalId": "da4c3ba7"
		},
		"chapter_cw9b9ylxk": {
			"name": "MDD/Unmet needs",
			"content": [
				"Brintellix_2",
				"Brintellix_3",
				"Brintellix_4",
				"Brintellix_5",
				"Brintellix_6",
				"Brintellix_7",
				"Brintellix_8",
				"Brintellix_NewAss_2"
			],
			"chapterExternalId": "2ceb09d2"
		},
		"chapter_w64ie8l2k": {
			"name": "Assessments",
			"content": [
				"Brintellix_10",
				"Brintellix_11",
				"Brintellix_12",
				"Brintellix_13",
				"Brintellix_14",
				"Brintellix_15",
				"Brintellix_16",
				"Brintellix_17",
				"Brintellix_18",
				"Brintellix_19"
			],
			"chapterExternalId": "94f05b5f"
		},
		"chapter_1ipblrd3v": {
			"name": "Feel Better",
			"content": [
				"Brintellix_20",
				"Brintellix_21",
				"Brintellix_22",
				"Brintellix_23",
				"Brintellix_24",
				"Brintellix_25",
				"Brintellix_26",
				"Brintellix_48"
			],
			"chapterExternalId": "8df325db"
		},
		"chapter_ccumrj4v4": {
			"name": "Think & Do Better",
			"content": [
				"Brintellix_27",
				"Brintellix_28",
				"Brintellix_29",
				"Brintellix_30",
				"Brintellix_31",
				"Brintellix_32",
				"Brintellix_33",
				"Brintellix_37",
				"Brintellix_38"
			],
			"chapterExternalId": "9d660d25"
		},
		"chapter_2ml2067dg": {
			"name": "Real-world Data",
			"content": [
				"Brintellix_39",
				"Brintellix_40",
				"Brintellix_41",
				"Brintellix_42",
				"Brintellix_43",
				"Brintellix_44",
				"Brintellix_45",
				"Brintellix_46",
				"Brintellix_NewAss_3"
			],
			"chapterExternalId": "a7a9558b"
		},
		"chapter_9htk88yrs": {
			"name": "Populations",
			"content": [
				"Brintellix_47",
				"Brintellix_49",
				"Brintellix_52",
				"Brintellix_34",
				"Brintellix_35",
				"Brintellix_NewAss_4"
			],
			"chapterExternalId": "f27f54e3"
		},
		"chapter_k1fohb8cn": {
			"name": "Tolerability",
			"content": [
				"Brintellix_55",
				"Brintellix_56"
			],
			"chapterExternalId": "a38a0e7c"
		},
		"chapter_m75rbybii": {
			"name": "MoA",
			"content": [
				"Brintellix_p194",
				"Brintellix_58"
			],
			"chapterExternalId": "2447eac6"
		},
		"chapter_co5e4l9u6": {
			"name": "Dosing",
			"content": [
				"Brintellix_59",
				"Brintellix_60",
				"Brintellix_NewAss_10",
				"Brintellix_NewAss_9",
				"Brintellix_61",
				"Brintellix_62"
			],
			"chapterExternalId": "c8300495"
		},
		"chapter_5dkfcngx5": {
			"name": "API_Ref",
			"content": [
				"Brintellix_63",
				"Brintellix_64"
			],
			"chapterExternalId": "02bd9110"
		},
		"chapter_ntw9pug98": {
			"name": "Patient Profiles",
			"content": [
				"Brintellix_65",
				"Brintellix_66",
				"Brintellix_67",
				"Brintellix_68",
				"Brintellix_69"
			],
			"chapterExternalId": "7abe8c55"
		},
		"chapter_do92xnh6a": {
			"name": "Study Designs",
			"content": [
				"Brintellix_70",
				"Brintellix_71",
				"Brintellix_72",
				"Brintellix_73",
				"Brintellix_74",
				"Brintellix_75",
				"Brintellix_76",
				"Brintellix_77",
				"Brintellix_78",
				"Brintellix_79",
				"Brintellix_80",
				"Brintellix_81",
				"Brintellix_82",
				"Brintellix_83",
				"Brintellix_84",
				"Brintellix_85",
				"Brintellix_86",
				"Brintellix_87",
				"Brintellix_88",
				"Brintellix_89",
				"Brintellix_91",
				"Brintellix_NewAss_7",
				"Brintellix_NewAss_8"
			],
			"chapterExternalId": "75dafb0d"
		},
		"chapter_ag9pvwxfd": {
			"name": "Populations 2",
			"content": [
				"Brintellix_36",
				"Brintellix_50",
				"Brintellix_NewAss_6",
				"Brintellix_41Copy2",
				"Brintellix_53",
				"Brintellix_54"
			],
			"chapterExternalId": "d2881466"
		}
	},
	"storyboard": [
		"main",
		"chapter_cw9b9ylxk",
		"chapter_w64ie8l2k",
		"chapter_1ipblrd3v",
		"chapter_ccumrj4v4",
		"chapter_2ml2067dg",
		"chapter_9htk88yrs",
		"chapter_ag9pvwxfd",
		"chapter_k1fohb8cn",
		"chapter_m75rbybii",
		"chapter_co5e4l9u6",
		"chapter_5dkfcngx5",
		"chapter_ntw9pug98",
		"chapter_do92xnh6a"
	]
}
